Key terms
About OMGA
Omega Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of DNA-sequence-targeting and mRNA-encoded therapeutics. It offers its product under the OMEGA platform. The company was founded by Noubar B. Afeyan and David Berry on July 13, 2016 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest OMGA news
May 13
6:27am ET
Buy Rating Reaffirmed for Omega Therapeutics on Strong Clinical and Financial Performance
May 06
10:45pm ET
Buy Rating Affirmed for Omega Therapeutics Amid Strong Financials and Promising OTX-2002 Clinical Trials
May 06
7:08am ET
Omega Therapeutics sees cash runway into 1Q25
May 06
7:07am ET
Omega Therapeutics reports Q2 EPS (36c), consensus (33c)
Apr 30
6:33am ET
Analysts Conflicted on These Healthcare Names: Annovis Bio (ANVS), Gilead Sciences (GILD) and Omega Therapeutics (OMGA)
Apr 16
4:23pm ET
Omega Therapeutics CFO Joshua Reed to depart
Apr 03
7:13am ET
Omega Therapeutics price target lowered to $9 from $10 at Piper Sandler
Apr 03
7:06am ET
Omega Therapeutics (OMGA) Receives a Buy from Piper Sandler
Mar 31
6:52pm ET
Omega Therapeutics price target lowered to $7 from $12 at Chardan
Mar 28
9:22am ET
Omega Therapeutics sees cash runway into 1Q25
Mar 28
9:21am ET
Omega Therapeutics announces strategic prioritization, reduces headcount by 35%
Mar 28
9:20am ET
Omega Therapeutics reports Q4 EPS (37c), consensus (45c)
No recent press releases are available for OMGA
OMGA Financials
Key terms
Ad Feedback
OMGA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
OMGA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range